Your Health, We Care
Balversa is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Balversa.
Balversa is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
from FDA,2024.01
Balversa is suitable for treating adult patients with locally advanced or metast···【more】
Release date：2026-01-05Recommended：5
Balversais a new target anti-cancer star, specializing in FGFR-positive cancers,···【more】
Release date：2024-08-26Recommended：224
Balversa, an innovative anti-cancer targeted drug, accurately snipes FGFR-positi···【more】
Release date：2024-08-26Recommended：256
Balversa is an innovative targeted therapy that effectively inhibits the growth ···【more】
Release date：2024-08-26Recommended：227
